Atypical Femur Fx Update. Faculty Disclosures
|
|
- Alyson Moore
- 6 years ago
- Views:
Transcription
1 Atypical Femur Fx Update Rick MD Faculty Disclosures Amgen Speaker Merck Speaker BioClinica Consultant. 2 The World Health Organization considers osteoporosis to be second only to cardiovascular diseases as a critical health problem, due to the high prevalence, costs and effect on quality of life caused by osteoporotic fractures 1
2 In the 30 seconds it took to go over that last slide 10 new osteoporosis-related fractures occurred in the world. Take that in every 3 seconds a new osteoporosis-related fracture occurs Yes my talk is on the risk of AFF but don t forget that 162 fractures are prevented with bisphosphonate treatment for every 1 AFF Adler RA, El-Hajj Fuleihan G, Bauer DC, Camacho PM, Clarke BL, Clines GA, et al. Managing osteoporosis in patients on long-term bisphosphonate treatment: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res 2016;31:16e35. What I ll Teach You What is an Atypical Femur Fx (AFF) The classic associations/causes of an AFF The radiographic finding of an AFF The incidence of AFF The treatment of an AFF What you should tell your patients about anti-osteoporosis meds, Drug Holidays, and risk 2
3 If we have time at the end Latest research on Drug Holidays Latest work on fracture prevention programs Future of Osteoporosis/Fracture Prevention Typical vs. Atypical Fracture 3
4 4
5 Revised ASBMR Case Definition (Excludes High Trauma, Peri-prosthetic and Pathologic Fractures) Revised ASBMR Case Definition (Excludes High Trauma, Peri-prosthetic and Pathologic Fractures) 5
6 New Major Criterion: Localized lateral cortex periosteal reaction Represents callus formation around a developing stress fracture All the participants agree that this seems to be a very specific feature of atypia and one that many investigators use to define atypical fractures This is also corroborated by the work of Feldstein and also of Aspenberg ASBMR Task Force AFF Bisphosphonates (BPs) and denosumab reduce the risk of spine and nonspine fractures. Atypical femur fractures (AFFs) have been reported in patients taking BPs, and in patients on denosumab Also occur in patients with no exposure to these drugs ASBMR Task Force AFF The association with specific diseases and drug exposures was removed from the minor features These associations should be sought rather than included in the case definition The requirement that fractures be noncomminuted was relaxed to include minimal comminution. The periosteal stress reaction at the fx site was changed from a minor to a major feature 6
7 14 months ago 3 months ago 7
8 Bisphosphonates similar structure to calcium hydroxyapatite molecule Mechanism killer of osteoclast! Bisphosphonates work by killing or seriously interfering with osteoclast. They are just one of several anti-resorptive agents Long lasting in bone - years or even decades 8
9 Warning of potential problems Dr Ott warned of potential theoretical complications of interfering with remodeling ever since the year 2000 For the most part we didn t take these warnings seriously until
10 The Dreaded Black Line 10
11 11
12 DBL - Dreaded Black Line 12
13 Summary KP SCAL ,835, years old 188,814 on Bisphosphonates (BP) 10% 142 pts with AFF -128 on BP (90%) Average age 69.3 ± 8.6 years Only 5 men 70 Asians (49.3%), 1 Black (0.7%), 12 Hispanics (8.5%), and 59 Whites (41.5%) 22.5% bilateral AFF 13
14 per 100, Santa Fe Bone Symposium Proportion of bisphosphonate-exposed patients with atypical fracture Duration of bisphosphonate use, years The odds ratio of developing an atypical femoral fracture range from Neviaser AS, Lane JM, Lenart BA, Edobor-Osula F, Lorich DG. Low-energy femoral shaft fractures associated with alendronate use. J Orthop Trauma May-Jun;22(5): Feldstein AC, Black D, Perrin N, Rosales AG, Friess D, Boardman D, R, Santora A, Chandler JM, Rix MM, Orwoll E. Incidence and demography of femur fractures with and without atypical features. J Bone Miner Res May;27(5): Schilcher J, Micha elsson K, Aspenberg P. Bisphosphonate use and atypical fractures of the femoral shaft. N Engl J Med May 5;364(18): Erratum in: N Engl J Med Oct 20;365(16): Park-Wyllie LY, Mamdani MM, Juurlink DN, Hawker GA, Gunraj N, Austin PC, Whelan DB,Weiler PJ, Laupacis A. Bisphosphonate use and the risk of subtrochanteric or femoral shaft fractures in older women. JAMA Feb 23;305(8): The odds ratio is very suspect because risk depends on multiple factors including: Age Sex Race Duration of treatment Time since stopping treatment Medical conditions/meds (steroids, HT) The highest risk is. A prior AFF on the contralateral femur 14
15 Years bisphosphonate Rx after 1st AFF Bilateral AFF - After index AFF No Bilateral AFF - After index AFF Incidence Bilateral AFF % % % % Atypical Femur Fractures The risk of a contralateral atypical femur fracture is decreased by 65.6% (p = 0.023) if bisphosphonates were stopped within the first year after the index atypical femur fracture. Key Points to Remember 15
16 #1 Is This A Stress (Atypical) Femur Fx Xray finding are key to understand Usually on bisphosphonates 5 years or more Younger patients than typical femur fxs Almost all women Prodromal pain in most patients (~70%) Often bilateral changes on xrays (~ 50%) More common in Asians and Whites Often taking steroids Findings and Stages Location - Subtrochanteric or Diaphysis Thick cortex laterally > than medially Flaring of lateral cortex with/without lucency Fx Transverse (lateral) short oblique Bilateral changes >50% Stage 1 Thick lateral cortex and pain Stage 2 Dreaded Black Line Stage 3 Complete fracture #2 What Are Complications of AFF Thick cortex and bowing on an AP view make placing a rod a challenge without over-reaming Delayed healing is common Stress Fx line may not heal while a bridging callus is common (rods are better than plates) 25% of patients fracture the other femur at same site (subtroch or shaft) Short rod may be bad idea 16
17 #3 Surgical Plan Plan for a long rod Over-ream if bowed or thick cortex Don t comminute the fracture Have blood available #4 Post-Op Plan Expect possible delayed healing, higher non-union Expect to see changes on the other femur in 50-70% of cases Expect the other femur to fracture ~18% if you stop bisphosphonates right away, higher if you continue bisphosphonates. #5 Post-Op Plan - Medication Stop the bisphosphonate Healing may be delayed If you see delayed healing consider an anabolic bone agent like PTH 17
18 Know the risk Have a plan Do the work 10-Year Risk of Fracture without Treatment 10-Year Risk of Fracture with Treatment Proportion 4 in 10 2 in 10 Probability 40% 20% Part-to-whole Icon Array Graph 18
19 Lewiecki EM. Curr Osteoporos Rep Comparative Risks x Any Fragility Fracture (1) Hip Fracture (1) Anaphylaxis from PCN Shot 32 Death by MVA 11 Death by Murder ONJ- Osteoporosis Patient Death by Lighting Strike in NM (1) Women age (from Swedish National Bureau of Statistics and database of Olmsted County, MN, USA.) Risk per 100,000 People per Year Kanis JA et al. Osteoporos Int. 2001;12: Pharmcoepidemiol Drug Saf. 2003;12: National Center for Health Statistics. JADA. 2006;137: Comparative Risks Any Fragility Fracture (1) Hip Fracture (1) Anaphylaxis from PCN Shot 32 Death by MVA 10 Death by Murder ONJ- Osteoporosis Patient Lighting Strike in NM (1) Women age (from Swedish National Bureau of Statistics and database of Olmsted County, MN, USA.) Risk per 100,000 People per Year Kanis JA et al. Osteoporos Int. 2001;12: Pharmcoepidemiol Drug Saf. 2003;12: National Center for Health Statistics. JADA. 2006;137: MMWR 47(19); Accessed 03/11/ Accessed 03/11/2017. Image copyright@2017 Lewiecki EM. 19
20 10-Year Probabilities x 80 year-old woman with FN T-score = -3.3 Includes 0.01% Atypical Femur Fracture Risk Includes 0.5% Atypical Femur Fracture Risk Untreated probability of major osteoporotic fracture calculated by FRAX. ONJ estimate is ~1/100,000 patienttreatment-years from ASBMR Task Force by Khosla S et al. J Bone Miner Res 2007;22: AFF estimate untreated is ~0.01/10,000 and treated is ~5/10,000 patient-years from Schilcher J et al. N Engl J Med. 2011;364: Risk estimates assume long-term bisphosphonate therapy resulting in 50% reduction in fracture risk. MVA and murder data from the CDC at Image copyright 2011 Lewiecki EM. Slide version. 10-Year Probabilities 80 year-old woman with FN T-score = -3.3 Includes 0.01% Atypical Femur Fracture Risk Includes 0.5% Atypical Femur Fracture Risk Untreated probability of major osteoporotic fracture calculated by FRAX. ONJ estimate is ~1/100,000 patienttreatment-years from ASBMR Task Force by Khosla S et al. J Bone Miner Res 2007;22: AFF estimate untreated is ~0.01/10,000 and treated is ~5/10,000 patient-years from Schilcher J et al. N Engl J Med. 2011;364: Risk estimates assume long-term bisphosphonate therapy resulting in 50% reduction in fracture risk. MVA and murder data from the CDC at Image copyright 2017 Lewiecki EM. Slide version. Benefits and Risks Motor Vehicle Accidents Osteoporosis Wearing seat belts reduces the risk of serious crash-related injuries and deaths by about 50% Treatment with bisphosphonates reduces the risk of fractures by about 50% There are about 2.3 million adults treated in ERs each year for injuries from MVAs and about 2 million osteoporotic fractures each year. The risk of seat belt injuries and serious side effects from osteoporosis treatment is very small in proportion to the benefits. Data from multiple sources. 20
21 Cohen JT et al. Health Affairs. 2007;26: Similar Risk with Aspirin and Cars Treatment/Activity Aspirin for prevention of CV disease and cancer in 50 year-old men Fatality Risk per 100,000 Person-years 10.4 Auto travel 11 Bicycling 2.1 Rock climbing 36 Cause of Death Stroke and noncerebral complications But what about the benefits? Cohen JT et al. Health Affairs. 2007;26: Comparative Risks of Transfusion Lee DH et al. Transfusion. 2003;43:
22 Communicating Risk Lifetime risk of breast cancer in a 50 year-old woman is 9% Schapira MM et al. Med Decis Making. 2001;21: Sequential Array Graphs of Fx Risk 75 year-old Caucasian woman with FN T-score = -3.0 Untreated Treated Sequential Array Graphs of Fx Risk 75 year-old Caucasian woman with FN T-score = % 10% 0.007%. Untreated Treated Treated ONJ 22
23 67 Why don t we see AFF in patients receiving yearly dosing of bisphosphonates like Zolidronic Acid (Reclast/Zometa) Why does the risk differ by duration of BP, race, prior BP The largest risk factor is a prior AFF Is every at the same inherent risk of getting an AFF Can we build a risk benefit calculator for bisphosphonates Why do we still use bisphosphonates besides generics being dirt cheap Other meds far less safe Approximately 107,000 hospitalizations and 3,200 to 16,500 deaths annually were found to be attributable to the use of NSAIDs in USA From 1999 to 2015, more than 183,000 people have died in the U.S. from overdoses related to prescription opioids (33,091 deaths in 2015) 1000 ER visits per day 23
24 24
25 DBL - Dreaded Black Line 25
Balancing the Risks and Benefits of Osteoporosis Treatment: part I: 3 to 5 years treatment
Balancing the Risks and Benefits of Osteoporosis Treatment: part I: 3 to 5 years treatment Dennis M. Black, PhD Department of Epidemiology and Biostatistics, UCSF Financial Disclosures (past 3 years) -Consulting
More informationOsteoporosis: How to Manage Long- Term Use of Bisphosphonates AKA Now What? David E Feinstein, DO, CCD November 15 th, 2017
Osteoporosis: How to Manage Long- Term Use of Bisphosphonates AKA Now What? David E Feinstein, DO, CCD November 15 th, 2017 Introduction A fracture due to OP occurs every 3 seconds around the world. 1
More informationAACE/ACE Osteoporosis Treatment Decision Tool
AACE/ACE Osteoporosis Treatment Decision Tool What is Osteoporosis? OSTEOPOROSIS is defined as reduced bone strength leading to an increased risk of fracture. Osteoporosis, or porous bones, occurs when
More informationMedicine and the Current Correlation Between Fosamax and Fractures
Medicine and the Current Correlation Between Fosamax and Fractures American Association for Justice Fosamax Telseminar June 22, 2011 2:00 3:30 pm EDT By: William B. Curtis Michael S. Wilson Curtis Law
More informationSubtrochanteric Femoral Fracture in a Patient on Alendronate Therapy: A Case Report
Subtrochanteric Femoral Fracture in a Patient on Alendronate Therapy: A Case Report K.C. Lakati 1, M.B.L. Lutomia 2 1 Nakuru Orthopedic Center, 2 Egerton University Medical School, Nakuru, Kenya. Correspondence
More informationDisclosures D. Black. Bisphosphonates: Background, Efficacy and Recent Controversies. Page 1. Research Funding: Novartis, Merck
Bisphosphonates: Background, Efficacy and Recent Controversies Disclosures D. Black Research Funding: Novartis, Merck Dennis M. Black, PhD Consulting: Amgen, Lilly, Zosano, Nycomed Dept. of Epidemiology
More informationTREATMENT OF OSTEOPOROSIS HOLIDAYS OR NO HOLIDAYS? Nelson B. Watts, MD OSTEOPOROSIS AND BONE HEALTH SERVICES CINCINNATI, OHIO
TREATMENT OF OSTEOPOROSIS HOLIDAYS OR NO HOLIDAYS? Nelson B. Watts, MD OSTEOPOROSIS AND BONE HEALTH SERVICES CINCINNATI, OHIO DISCLOSURES Honoraria: Amgen, Merck, Shire Consulting : AbbVie, Amgen, Merck,
More informationAtypical Femoral Fracture: 2015 Position Statement of the Korean Society for Bone and Mineral Research
J Bone Metab 2015;22:87-91 http://dx.doi.org/10.11005/jbm.2015.22.3.87 pissn 2287-6375 eissn 2287-7029 Review Article Atypical Femoral Fracture: 2015 Position Statement of the Korean Society for Bone and
More informationCIC Edizioni Internazionali
Knowledge gap among general practitioners, endocrinologists and orthopedic surgeons regarding atypical lesions and fractures of the femur due to long-term use of bisphosphonates Eran Keltz 1 Igor Doronov
More informationWho cares about fractures! is more important. October 3, 2014 CSIM Workshop Brian Wirzba, MD, FRCPC, FACP Clinical Professor Grey Nuns Hospital
Isn t Osteoporosis just a T Score less than 2.5?? Who cares about fractures! is more important. Why do I need to know this? October 3, 2014 CSIM Workshop Brian Wirzba, MD, FRCPC, FACP Clinical Professor
More informationOsteoporosis: A Tale of 3 Task Forces!
Osteoporosis: A Tale of 3 Task Forces! Robert A. Adler, MD McGuire Veterans Affairs Medical Center Virginia Commonwealth University Richmond, Virginia, USA Disclosures The opinions are those of the speaker
More informationDrug Intervals (Holidays) with Oral Bisphosphonates
Drug Intervals (Holidays) with Oral Bisphosphonates Rizwan Rajak Consultant Rheumatologist & Lead for Osteoporosis GP Postgraduate Meeting April 2018 Contents Case presentation Pathway for Bisphosphonate
More informationA Brief History of Osteoporosis
Challenges in the Treatment of Osteoporosis Disclosure Institutional Grant / Research Support Amgen Consulting Amgen, Radius, Shire, Alexion Speaking Shire, Alexion E. Michael Lewiecki, MD New Mexico Clinical
More informationMonitoring Osteoporosis Therapy
Monitoring Osteoporosis Therapy SUZANNE MORIN DEPT OF MEDICINE, DIVISION OF GENERAL INTERNAL MEDICINE, MUHC CENTRE FOR OUTCOMES RESEARCH AND EVALUATION, RI MUHC November 2017 Conflict of Interest Disclosures
More informationATYPICAL FEMORAL FRACTURES AFTER LONG-TERM BISPHOS- PHONATES THERAPY: CASE REPORT
Rev. Med. Chir. Soc. Med. Nat., Iaşi 2016 vol. 120, no. 1 INTERNAL MEDICINE - PEDIATRICS CASE REPORTS ATYPICAL FEMORAL FRACTURES AFTER LONG-TERM BISPHOS- PHONATES THERAPY: CASE REPORT Corina Găleşanu 1,3*,
More informationPage 1. New Developments in Osteoporosis. What s New in Osteoporosis
New Developments in Osteoporosis Eliseo J. Pérez-Stable MD Professor of Medicine Division of General Internal Medicine Department of Medicine July 4, 2013 Declaration of full disclosure: No conflict of
More informationPage 1. Diagnosis and Treatment of Osteoporosis: What s New and Controversial in 2018? What s New in Osteoporosis
Diagnosis and Treatment of Osteoporosis: What s New and Controversial in 2018? Douglas C. Bauer, MD Professor of Medicine and Epidemiology & Biostatistics University of California, San Francisco What s
More informationFrom Fragile to Firm. Monika Starosta MD. Advocate Medical Group
From Fragile to Firm Monika Starosta MD Advocate Medical Group Bone Remodeling 10% remodeled each year Calcium homoeostasis Maintain Mechanical strength Replace Osteocytes Release Growth Factors Bone remodeling
More information1/28/2017. Orthopedic Implications Of Osteoporosis Introduction. Orthopedic Implications Of Osteoporosis Introduction
The Orthopedic Implications Of Prolonged In Osteoporosis Donald A. Wiss MD Director Of Orthopedic Trauma Cedars Sinai Medical Center Orthopedic Implications Of Osteoporosis Introduction Osteoporosis Most
More informationLearning Objectives. Controversies in Osteoporosis Prevention and Management. Etiology. Presenter Disclosure Information. Epidemiology.
12:45 1:30pm Controversies in Osteoporosis Prevention and Management SPEAKER Carolyn Crandall, MD, MS Presenter Disclosure Information The following relationships exist related to this presentation: Carolyn
More informationAtypical Femoral Fractures Insights and Enigmas
Atypical Femoral Fractures Insights and Enigmas Madhu Mehta, M.D. Clinical Asst. Prof. of Medicine Department of Immunology/Rheumatology The Ohio State University Abreviations used TFF- Typical femoral
More informationOsteoporosis: An Overview. Carolyn J. Crandall, MD, MS
Osteoporosis: An Overview Carolyn J. Crandall, MD, MS Osteoporosis: An Overview Carolyn J. Crandall, MD, MS Professor of Medicine David Geffen School of Medicine at UCLA Objectives Review osteoporosis
More informationLearning Objectives. Controversies in Osteoporosis Prevention and Management. Definition. Presenter Disclosure Information.
4 4:45 pm Controversies in Osteoporosis Prevention and Management SPEAKER Carolyn Crandall, MD, MS Presenter Disclosure Information The following relationships exist related to this presentation: Carolyn
More informationDiagnosis and Treatment of Osteoporosis: What s New and Controversial in ? What s New in Osteoporosis
Diagnosis and Treatment of Osteoporosis: What s New and Controversial in 2018-19? What s New in Osteoporosis The crisis in treatment and compliance Douglas C. Bauer, MD Professor of Medicine and Epidemiology
More informationMisuse of Bisphosphonates. Dr Rukhsana Parvin Associate Professor Department of Medicine Enam Medical College & Hospital
Misuse of Bisphosphonates Dr Rukhsana Parvin Associate Professor Department of Medicine Enam Medical College & Hospital Introduction Bisphosphonates are chemically stable analogues of pyrophosphate compounds.
More informationTherapeutic Updates in the Prevention and Treatment of Osteoporosis
Therapeutic Updates in the Prevention and Treatment of Osteoporosis 2013 Fall Managed Care Forum Las Vegas November 15, 2013 Steven T Harris MD FACP Clinical Professor of Medicine University of California,
More informationDownload slides:
Download slides: https://www.tinyurl.com/m67zcnn https://tinyurl.com/kazchbn OSTEOPOROSIS REVIEW AND UPDATE Boca Raton Regional Hospital Internal Medicine Conference 2017 Benjamin Wang, M.D., FRCPC Division
More informationControversies in Osteoporosis Management
Controversies in Osteoporosis Management 2018 Northwest Rheumatism Society Meeting Portland, OR April 28, 2018 Michael R. McClung, MD, FACP Director, Oregon Osteoporosis Center Portland, Oregon, USA Institute
More informationCurrent and Emerging Strategies for Osteoporosis
Current and Emerging Strategies for Osteoporosis I have nothing to disclose. Anne Schafer, MD Assistant Professor of Medicine Division of Endocrinology & Metabolism December 12, 2014 Outline Osteoporosis
More informationCurrent Issues in Osteoporosis
Current Issues in Osteoporosis California AACE 18TH Annual Meeting & Symposium Marina del Rey, CA September 15, 2018 Michael R. McClung, MD, FACP,FACE Director, Oregon Osteoporosis Center Portland, Oregon,
More informationCalcium, Vitamin D and Bisphosphonates: Disclosures. Benefits, Risks and Drug Holiday. Calcium YES or NO? Calcium Bad News!!
Calcium, Vitamin D and Bisphosphonates: Benefits, Risks and Drug Holiday Disclosures I am disclosing financial relationships as follows: Global Advisory Boards: Amgen, Lilly, Merck, Novartis Research grants:
More informationAtypical Subtrochanteric and Diaphyseal Femoral Fractures: Second Report of a Task Force of the American Society for Bone and Mineral Research
REVIEW JBMR Atypical Subtrochanteric and Diaphyseal Femoral Fractures: Second Report of a Task Force of the American Society for Bone and Mineral Research Elizabeth Shane,* David Burr,* Bo Abrahamsen,
More informationOsteoporosis in Men. CME Away India & Sri Lanka March 23 - April 7, 2018
Osteoporosis in Men CME Away India & Sri Lanka March 23 - April 7, 2018 Richard A. Bebb MD, ABIM, FRCPC Consultant Endocrinologist Medical Subspecialty Institute Cleveland Clinic Abu Dhabi Copyright 2017
More information9/9/2015 OSTEOPOROSIS WHAT S NEW AND ON THE HORIZON IN SCREENING, DRUG HOLIDAYS, SUPPLEMENTS, CONSERVATIVE THERAPY DISCLOSURES
OSTEOPOROSIS WHAT S NEW AND ON THE HORIZON IN SCREENING, DRUG HOLIDAYS, SUPPLEMENTS, CONSERVATIVE THERAPY Nelson B. Watts, MD OSTEOPOROSIS AND BONE HEALTH SERVICES CINCINNATI, OHIO DISCLOSURES Stock options/holdings,
More informationTreatments for Osteoporosis Expected Benefits, Potential Harms and Drug Holidays. Suzanne Morin MD FRCP FACP McGill University May 2014
Treatments for Osteoporosis Expected Benefits, Potential Harms and Drug Holidays Suzanne Morin MD FRCP FACP McGill University May 2014 Learning Objectives Overview of osteoporosis management Outline efficacy
More informationDisclosure. Objectives. Osteoporosis. Major Public Health Concern Will I end up like my mother?
Everything a Pharmacist Needs to Know About Osteoporosis New Mexico Pharmacists Association Mid-Winter Meeting January 27-28, 2018 Albuquerque, NM Consulting Amgen, Radius Speaking Radius Disclosure E.
More informationValidation Study of Claims-based Definitions of Suspected Atypical Femoral Fractures Using Clinical Information
薬剤疫学 Jpn J Pharmacoepidemiol, 1 1) June 16:1 〇 Original Article Validation Study of Claims-based Definitions of Suspected Atypical Femoral Fractures Using Clinical Information Shiro TANAKA 1, Hiroshi HAGINO,
More informationCASE 1 WHY IS IT IMPORTANT TO TREAT? FACTS CONCERNS
4:30-5:15pm Ask the Expert: Osteoporosis SPEAKERS Silvina Levis, MD OSTEOPOROSIS - FACTS 1:3 older women and 1:5 older men will have a fragility fracture after age 50 After 3 years of treatment, depending
More informationAtypical Femoral Fractures With Long Term Bisphosphonates Use
Atypical Femoral Fractures With Long Term Bisphosphonates Use There has been an increase in the number of atypical femoral fractures in pa4ents on long term bisphosphonate therapy (e.g Fosamax) Accordingly
More informationUsing GE Lunar DXA to Quantify, Visualize, and Trend Incipient Atypical Femoral Fractures
Using GE Lunar DXA to Quantify, Visualize, and Trend Incipient Atypical Femoral Fractures The management of osteoporosis underwent a paradigm shift in 1995 with the approval of the first bisphosphonate,
More information2017 Santa Fe Bone Symposium McClung
217 Santa Fe Bone Symposium Insights into the Use of Anti-remodeling and Anabolic Agents for Osteoporosis Developing a Long-term Management Plan Michael R., MD, FACP Oregon Osteoporosis Center Portland,
More informationOSTEOPOROSIS IN MEN. Nelson B. Watts, MD OSTEOPOROSIS AND BONE HEALTH SERVICES CINCINNATI, OHIO
OSTEOPOROSIS IN MEN Nelson B. Watts, MD OSTEOPOROSIS AND BONE HEALTH SERVICES CINCINNATI, OHIO DISCLOSURES Speakers Bureau: Amgen, Radius Consultant: Abbvie, Amgen, Janssen, Radius, Sanofi Watts NB et
More informationACP Colorado-Evidence Based Management of Osteoporosis
ACP Colorado-Evidence Based Management of Osteoporosis Micol S. Rothman, MD Associate Professor of Medicine and Radiology Clinical Director Metabolic Bone Program University of Colorado School of Medicine
More informationFracture=Bone Attack:
Fracture=Bone Attack: Linking Hip Fractures to Osteoporosis Care Angela M. Cheung, MD, PhD, FRCPC Professor of Medicine, University of Toronto Potential Conflicts of Interests Industry Grants (to UHN)
More informationOsteoporosis: A Tale of 3 Task Forces!
Osteoporosis: A Tale of 3 Task Forces! Robert A. Adler, MD McGuire Veterans Affairs Medical Center Virginia Commonwealth University Richmond, Virginia, USA Disclosures The opinions are those of the speaker
More informationBisphosponate Fractures: Elusive but Dangerous
Krista Weiss, 2014 Gillian Lieberman, MD October 25, 2013 Bisphosponate Fractures: Elusive but Dangerous Krista Weiss, Tufts Medical School Year IV Gillian Lieberman, MD Presentation Outline Our Patient:
More informationTask Force Co-Chairs. Members
Managing Osteoporosis Patients After Long-Term Bisphosphonate Treatment Report of a Task Force* of the American Society for Bone and Mineral Research Robert A. Adler, MD Task Force Co-Chairs Ghada El-Hajj
More informationOsteoporosis Management in Older Adults
Osteoporosis Management in Older Adults Angela M Cheung, MD, PhD, FRCPC, CCD Professor of Medicine, University of Toronto Disclosures Relationship with Commercial Entities: Honoraria from: Amgen, Eli Lilly,
More informationClinical Analysis of Femur Shaft Insufficiency Fractures
Original Article Clinics in Orthopedic Surgery 2012;4:227-233 http://dx.doi.org/10.4055/cios.2012.4.3.227 Clinical Analysis of Femur Shaft Insufficiency Fractures Sang-Bong Ko, MD, Sang-Wook Lee, MD, Chang-Min
More informationPage 1. Current and Emerging Strategies for Osteoporosis. Osteoporosis Warm-Up: Which of the Following is True?
Current and Emerging Strategies for Osteoporosis Douglas C. Bauer, MD Professor of Medicine and Epidemiology & Biostatistics University of California, San Francisco No Disclosures Osteoporosis Warm-Up:
More informationPage 1. Current and Emerging Strategies What s New in Osteoporosis. Osteoporosis. What is Osteoporosis? Traditional Risk Factors for Fracture
Current and Emerging Strategies for Osteoporosis What s New in Osteoporosis Risk stratification Douglas C. Bauer, MD University of California, San Francisco Under recognition and poor compliance New potential
More informationPage 1. Osteoporosis Warm-Up: Which of the Following is True? Diagnosis and Treatment of Osteoporosis: What is New in What s New in Osteoporosis
Diagnosis and Treatment of Osteoporosis: What is New in 2017 Douglas C. Bauer, MD Professor of Medicine and Epidemiology & Biostatistics University of California, San Francisco No Disclosures Osteoporosis
More informationFemoral Shaft Cortical Pathology associated with longterm Alendronate Therapy: A New Classification
Malaysian Orthopaedic Journal 2013 Vol 7 No 3 Doi:http://dx.doi.org/10.5704/MOJ.1307.008 MK Kwan, et al Femoral Shaft Cortical Pathology associated with longterm Alendronate Therapy: A New Classification
More informationUpdates in Osteoporosis. I have no conflicts of interest. What Would You Do? Mrs. C. What s New in Osteoporosis. Page 1
Updates in Osteoporosis Jeffrey A. Tice, MD Associate Professor of Medicine Division of General Internal Medicine, University of California, San Francisco I have no conflicts of interest What s New in
More informationOsteoporosis TreatmentUpdate November 2018
Osteoporosis TreatmentUpdate November 2018 Robert A. Adler, MD McGuire Veterans Affairs Medical Center Virginia Commonwealth University Richmond, Virginia, USA Disclosures Opinions are those of the speaker
More informationA Review of Bone Health Issues in Oncology
A Review of Bone Health Issues in Oncology David L. Kendler MD FRCPC CCD Professor of Medicine (Endocrinology) University of British Columbia Vancouver Canada Disclosures David Kendler has received research
More informationPresenter: 翁家嫻 Venue date:
FOR THE TREATMENT OF OSTEOPOROSIS IN POSTMENOPAUSAL WOMEN AT INCREASED RISK OF FRACTURES 1 Presenter: 翁家嫻 Venue date: 2018.03.13 PMO: postmenopausal osteoporosis. 1. Prolia (denosumab), Summary of Product
More informationUpdate in Osteoporosis: Disclosures. Topics
Update in Osteoporosis: 21 Michael Maricic, M.D. Catalina Pointe Rheumatogy Clinical Associate Professor of Medicine University of Arizona Disclosures Speakers Bureau, Consultant or Clinical Research Grant
More informationAssessment and Treatment of Osteoporosis Professor T.Masud
Assessment and Treatment of Osteoporosis Professor T.Masud Nottingham University Hospitals NHS Trust University of Nottingham University of Derby University of Southern Denmark What is Osteoporosis? Osteoporosis
More informationFRAX assessment. The patient. The patient. Which drug? UK NOGG Guidance 3/22/17. Safety issues with osteoporosis treatments
The patient Safety issues with osteoporosis treatments 78 year-old lady, retired dentist, active. Family history of osteoporosis (mother, younger sister). Humerus fracture 3 months ago. Type 2 diabetes
More informationRheumatology. keeping Joints in Motion. Treating and Preventing Fractures
Rheumatology keeping Joints in Motion Treating and Preventing Fractures Robin K. Dore, MD Clinical Professor of Medicine David Geffen School of Medicine at UCLA, Los Angeles CA Private practice, Tustin
More informationRefracture Prevention The Role of Primary Care
MonashHealth Refracture Prevention The Role of Primary Care Professor Peter R Ebeling AO MBBS MD FRACP Head, Department of Medicine School for Clinical Sciences Monash Health Translation Precinct Monash
More informationBisphosphonate Use and Atypical Fractures of the Femoral Shaft
T h e n e w e ngl a nd j o u r na l o f m e dic i n e original article Bisphosphonate Use and Atypical Fractures of the Femoral Shaft Jörg Schilcher, M.D., Karl Michaëlsson, M.D., Ph.D., and Per Aspenberg,
More informationOsteoporosis. Overview
v2 Osteoporosis Overview Osteoporosis is defined as compromised bone strength that increases risk of fracture (NIH Consensus Conference, 2000). Bone strength is characterized by bone mineral density (BMD)
More informationBisphosphonate-related bilateral atypical femoral fractures be aware and beware
Case Report Bisphosphonate-related bilateral atypical femoral fractures be aware and beware Ruben Depasquale, Claire Matthews, Victor N. Cassar-Pullicino Abstract Although bisphosphonates have a well established
More informationOsteoporosis Update. Case 2. Case 1: Monday morning, 8:15
Osteoporosis Update Laura E. Ryan, MD Assistant Director for Special Programs Center for Women s Health Clinical Assistant Professor of Medicine Division of Endocrinology, Diabetes and Metabolism The Ohio
More informationAACE. Orlando Drug Holidays. Disclosures. Advisory boards: Alexion, Amgen, Lilly, Merck, Radius Health
AACE Orlando 2016 Drug Holidays Disclosures Advisory boards: Alexion, Amgen, Lilly, Merck, Radius Health Scientific grants: Alexion, Amgen, Immunodiagnostics, Lilly, Merck, Regeneron, Radius Health, Roche
More informationChau Nguyen, D.O. Rheumatologist Clinical Assistant Professor of Internal Medicine at Western University of Health Sciences
Chau Nguyen, D.O Rheumatologist Clinical Assistant Professor of Internal Medicine at Western University of Health Sciences I do not have any relationship with the manufacturer of any commercial products
More informationFrequency of Incomplete Atypical Femoral Fractures in Asymptomatic Patients on Long- Term Bisphosphonate Therapy
Musculoskeletal Imaging Original Research La Rocca Vieira et al. Femoral Fractures in Asymptomatic Patients Musculoskeletal Imaging Original Research Renata La Rocca Vieira 1 Zehava Sadka Rosenberg 1 Mary
More informationOsteoporosis Management
Osteoporosis Management Lisa Voss PA C, CCD Laura Frontiero NP C, CCD Kaiser Healthy Bones Program San Diego Disclosures: Nothing to disclose www.zazzle.com 1 Overview How to diagnose Osteoporosis FRAX
More informationCurrent and Emerging Approaches for Osteoporosis
Current and Emerging Approaches for Osteoporosis Douglas C. Bauer, MD Professor of Medicine and Epidemiology & Biostatistics University of California, San Francisco No Disclosures What s New in Osteoporosis
More informationAn Update on Osteoporosis Treatments
An Update on Osteoporosis Treatments Dr Mike Stone University Hospital Llandough Treatments for osteoporosis Calcium and vitamin D HRT Raloxifene Etidronate Alendronate Risedronate Ibandronate (oral and
More informationSpongeBone Menopants*
SpongeBone Menopants* Adam Fershko, MD, FACP Kettering Health Network *Postmenopausal Osteoporosis Objectives O Epidemiology O Clinical significance O Pathophysiology O Screening and Diagnosis O Treatment
More informationManagement of postmenopausal osteoporosis
Management of postmenopausal osteoporosis Yeap SS, Hew FL, Chan SP, on behalf of the Malaysian Osteoporosis Society Committee Working Group for the Clinical Guidance on the Management of Osteoporosis,
More informationOsteoporosis: Are your bones at risk of fracturing? Rachel Wallwork, MD Internal medicine resident Massachusetts General Hospital
Osteoporosis: Are your bones at risk of fracturing? Rachel Wallwork, MD Internal medicine resident Massachusetts General Hospital What is Osteoporosis? Osteoporosis causes bones to lose density, become
More informationOsteoporosis Agents Drug Class Prior Authorization Protocol
Osteoporosis Agents Drug Class Prior Authorization Protocol Line of Business: Medicaid P&T Approval Date: February 21, 2018 Effective Date: April 1, 2018 This policy has been developed through review of
More informationAdvanced medicine conference. Monday 20 Tuesday 21 June 2016
Advanced medicine conference Monday 20 Tuesday 21 June 2016 Osteoporosis: recent advances in risk assessment and management Juliet Compston Emeritus Professor of Bone Medicine Cambridge Biomedical Campus
More informationOsteoporosis Evaluation and Treatment
Osteoporosis Evaluation and Treatment Anne Schafer, MD Assistant Professor of Medicine Division of Endocrinology & Metabolism October 28, 2011 No conflicts of interest Objectives Explain when to initiate
More informationAmong the most important concerns regarding the
140 Osteoporosis An Update Stephen Honig, M.D., M.Sc., and Gregory Chang, M.D. Abstract The past year has been a dynamic one for clinicians and researchers with an interest in osteoporosis. This update
More informationOsteoporosis update. Dr. Claire Vandevelde Consultant Rheumatologist, LTHT
Osteoporosis update Dr. Claire Vandevelde Consultant Rheumatologist, LTHT Outline Background BMD Tools for assessing fracture risk Case study Denosumab Treatment breaks BMD BMD predicts fracture risk but
More informationHot Topics in Osteoporosis and Fracture Prevention
Hot Topics in Osteoporosis and Fracture Prevention Sid Feldman, MD CCFP (COE) FCFP Sandra Kim, MD, FRCPC November 15, 2018 Family Medicine Forum, Toronto Faculty/Presenter Disclosure Faculty: Sid Feldman
More informationHow to treat osteoporosis With what and for how long?
How to treat osteoporosis With what and for how long? Professor Neil Gittoes Consultant Endocrinologist & Honorary Professor Where will we be going? Drug therapies Current Indications Contraindications/unmet
More informationPage 1. Updates in Osteoporosis. I have no conflicts of interest. What is osteoporosis? What s New in Osteoporosis
Updates in Osteoporosis Jeffrey A. Tice, MD Professor of Medicine Division of General Internal Medicine, University of California, San Francisco I have no conflicts of interest What s New in Osteoporosis
More informationOTA Highlight Paper. Surgical Treatment Improves Clinical and Functional ACCEPTED. Outcomes for Patients who Sustain Incomplete
Journal of Orthopaedic Trauma Publish Ahead of Print DOI: 10.1097/BOT.0b013e31827240ae OTA Highlight Paper Surgical Treatment Improves Clinical and Functional Outcomes for Patients who Sustain Incomplete
More informationOsteoporosis challenges
Osteoporosis challenges Osteoporosis challenges Who should have a fracture risk assessment? Who to treat? Drugs, holidays and unusual adverse effects Fracture liaison service? The size of the problem 1
More informationDisclosures. Diagnostic Challenges in Osteoporosis: Whom To Treat 9/25/2014
Disclosures Diagnostic Challenges in Osteoporosis: Whom To Treat Ethel S. Siris, MD Columbia University Medical Center New York, NY Consultant on scientific issues for: AgNovos Amgen Eli Lilly Merck Novartis
More informationEpidemiology and Consequences of Fractures
Epidemiology and Consequences of Fractures Ann V. Schwartz, PhD Department of Epidemiology and Biostatistics UCSF Financial Disclosures Advisory Board: Amgen Research Support: Hologic 24July12 1 Outline
More informationWhat is Osteoporosis?
What is Osteoporosis? 2000 NIH Definition A skeletal disorder characterized by compromised bone strength predisposing a person to an increased risk of fracture. Bone strength reflects the integration of
More informationOsteoporosis Update. Greg Summers Consultant Rheumatologist
Osteoporosis Update Greg Summers Consultant Rheumatologist DEFINITION OSTEOPOROSIS is LOW BONE MASS (& micro-architectural deterioration) causing AN INCREASED RISK OF FRACTURE 23 years 82 years 23 y/o
More informationAtypical femoral fractures (AFFs) have recently. Scoring System for Identifying Impending Complete Fractures in Incomplete Atypical Femoral Fractures
CLINICAL RESEARCH ARTICLE Scoring System for Identifying Impending Complete Fractures in Incomplete Atypical Femoral Fractures Byung-Woo Min, 1 * Kyung-Hoi Koo, 2 * Youn-Soo Park, 3 Chang-Wug Oh, 4 Seung-Jae
More informationDISCLOSURES SUNDEEP KHOSLA, M.D.
ADDRESSING PATIENT CONCERNS REGARDING COMPLICATIONS OF ANTIRESORPTIVE THERAPY Sundeep Khosla, M.D. Mayo Clinic, Rochester, MN DISCLOSURES SUNDEEP KHOSLA, M.D. NONE 1 OVERALL CONCLUSIONS There has been
More informationUpdate on Osteoporosis 2016
WELCOME! Update on Osteoporosis 2016 Jennifer J. Kelly, D.O., F.A.C.E. Associate Professor of Medicine Division of Endocrinology, Diabetes and Metabolism Upstate Medical University Director of the Clinical
More informationAnnual Rheumatology & Therapeutics Review for Organizations & Societies
Annual Rheumatology & Therapeutics Review for Organizations & Societies Biochemical Markers of Bone Turnover: Definitions and Recommendations for Monitoring Therapy Learning Objectives for Biochemical
More informationLong-term Osteoporosis Therapy What To Do After 5 Years?
Long-term Osteoporosis Therapy What To Do After 5 Years? Developing a Long-term Management Plan North American Menopause Society Philadelphia, PA October 11, 2017 Michael R. McClung, MD, FACP Institute
More informationUpcoming Agents for Osteoporosis
Upcoming Agents for Osteoporosis May 5, 2017 Michael R. McClung, MD, FACP Director, Oregon Osteoporosis Center Portland, Oregon, USA Professorial Fellow, Institute of Health and Ageing Australian Catholic
More informationModule 5 - Speaking of Bones Osteoporosis For Health Professionals: Fracture Risk Assessment. William D. Leslie, MD MSc FRCPC
Module 5 - Speaking of Bones Osteoporosis For Health Professionals: Fracture Risk Assessment William D. Leslie, MD MSc FRCPC Case #1 Age 53: 3 years post-menopause Has always enjoyed excellent health with
More informationBone Health Update Susan L. Greenspan, MD Professor of Medicine University of Pittsburgh
Bone Health Update 2018 Susan L. Greenspan, MD Professor of Medicine University of Pittsburgh The Problem 50% women and 20% of men have an osteoporotic fracture after age 50 2 million fractures annually
More informationJuly 2012 CME (35 minutes) 7/12/2016
Financial Disclosures Epidemiology and Consequences of Fractures Advisory Board: Amgen Janssen Pharmaceuticals Inc. Ann V. Schwartz, PhD Department of Epidemiology and Biostatistics UCSF Outline Osteoporotic
More informationAtypical Femoral Fractures: An Orthopaedic Surgeon s Perspective
Curr Transl Geriatr and Exp Gerontol Rep (2013) 2:91 98 DOI 10.1007/s13670-013-0045-6 GERIATRIC ORTHOPEDICS (EG MEINBERG, SECTION EDITOR) Atypical Femoral Fractures: An Orthopaedic Surgeon s Perspective
More informationOsteoporosis Update : The Transplant Patient, Cases & Questions
Osteoporosis Update : The Transplant Patient, Cases & Questions Bobo Tanner MD Director, Osteoporosis Clinic Marni Groves, NP Division of Rheumatology & Allergy Vanderbilt University Nashville TN Sept.
More information